Search results
Results From The WOW.Com Content Network
According to the U.S. Food and Drug Administration (FDA), naltrexone/bupropion is contraindicated in patients who have/are: [4] History of seizures; History of an eating disorder such as bulimia nervosa or anorexia nervosa; Taking opioids, or are in opiate withdrawal. Taken monoamine oxidase inhibitors in the last 14 days; Pregnant
Lisdexamfetamine is an FDA-approved appetite suppressant drug that is indicated (i.e., used clinically) for the treatment of binge eating disorder. [19] The antidepressant fluoxetine is a medication that is approved by the Food and Drug Administration for the treatment of an eating disorder, specifically bulimia nervosa.
Fluoxetine, sold under the brand name Prozac, among others, is an antidepressant medication of the selective serotonin reuptake inhibitor (SSRI) class [2] used for the treatment of major depressive disorder, anxiety, obsessive–compulsive disorder (OCD), panic disorder, premenstrual dysphoric disorder, and bulimia nervosa. [2] It is also ...
It was approved by the U.S. Food and Drug Administration (FDA) in November 1997 [24] for the treatment of obesity. Sibutramine is reported to be a prodrug to two active metabolites , desmethylsibutramine (M1; BTS-54354) and didesmethylsibutramine (M2; BTS-54505), with much greater potency as monoamine reuptake inhibitors.
Just approved by the FDA last year, this new drugcombines dextromethorphan and bupropion (Wellbutrin). And like esketamine, it works fast. And like esketamine, it works fast. In clinical trials ...
Bulimia nervosa may affect up to 1% of young women and, after 10 years of diagnosis, half will recover fully, a third will recover partially, and 10–20% will still have symptoms. [4] Adolescents with bulimia nervosa are more likely to have self-imposed perfectionism and compulsivity issues in eating compared to their peers. This means that ...
Mirikizumab, a drug currently approved by the Food and Drug Administration (FDA) for the treatment of ulcerative colitis, also sends Crohn's disease into clinical remission, new findings suggest.
For premium support please call: 800-290-4726 more ways to reach us